Innovative Cardiology Platform Poised for Growth with Latest Funding Round Led by General Catalyst

WASHINGTON, March 6, 2024 — Chamber Cardio (Chamber), a technology-enabled cardiology solution, announced today an $8 million seed round led by General Catalyst with support from existing investor AlleyCorp and participation from Company Ventures, American Family Ventures, and City Light. In an industry where the transition to value-based care remains limited among cardiologists, Chamber emerges as a dedicated partner, uniquely positioned to support and collaborate with cardiology practices.

Cardiovascular disease drives over $400 billion in annual healthcare expenditures, and Chamber aims to tackle this issue head-on by making the transition to value-based care more accessible. The funding will be utilized to further develop Chamber’s technology, expand the cardiology network nationally, and grow the team.

“Cardiovascular care, a top cause of U.S. mortality and financial challenge for health plans, is expected to intensify with rising disease, aging populations, and complex supply dynamics,” said Chris Bischoff, Managing Director at General Catalyst. “Our partnership with Chamber aims to shift cardiology care toward value, enhancing access to high-quality care and lowering healthcare costs, which are core tenets of our Health Assurance thesis.”

Chamber was founded in response to challenges expressed by cardiologists nationwide. Many voiced their frustration with the lack of technology to effectively care for their population, inability to negotiate with payers, and secure value-based deals based on quality. Chamber addresses this by equipping cardiologists with real-time insights, evidence-based guidelines, care teams, and contracting support to streamline workflows, enabling them to focus on patient care. The company’s mission is to empower cardiologists to operate in a value-based world where they are compensated for delivering the right care at the right time.

“Our objective is to provide unparalleled support to cardiologists as they navigate the transition to value-based care, putting them in control of their practice,” said George Aloth, Co-Founder and CEO of Chamber. “By doing so, we aim to provide patients with the highest quality of care, ultimately improving health outcomes for heart disease.”

Co-Founded by George Aloth, former President & CEO of a BCBS health plan and kidney care VBC executive; Dr. Sameer Sheth, a cardiologist and digital health leader; and Dr. Jeffrey De Flavio, a Co-Founder of Pearl Health and founding CEO of Groups Recover Together, Chamber’s team has deep expertise in operating and navigating the complexities of value-based care. Chamber is the premier solution for both cardiologists and payers to improve the health outcomes for individuals with cardiovascular disease.

“The multi-trillion dollar shift to outcome driven reimbursement is accelerating across healthcare, especially in cardiology,” said Dr. Jeffrey De Flavio, Co-Founder and Executive Chairman of Chamber. “Cardiologists and insurers are seizing this opportunity to improve care and align reimbursement with our industry leading technology.”

Chamber is actively managing patients in the Mid-Atlantic region with ambitious plans for nationwide expansion. In addition to existing payer partnerships, Chamber is looking to rapidly grow their cardiology network. Visit www.chambercardio.com to explore opportunities for practices and payers to partner with Chamber and discover how you can join a dynamic and growing team.

About Chamber 
Chamber is dedicated to supporting cardiology practices through technology-enabled delivery. Co-founded by healthcare industry leaders George Aloth, Dr. Sameer Sheth, and Dr. Jeffrey De Flavio, Chamber empowers cardiologists to thrive in a value-based care landscape, ensuring improved patient outcomes and increased practice success.

SOURCE Chamber Cardio

The collaboration will fund climate technology companies scaling solutions focused on community impact 

HONOLULU, March 6, 2024 — Wells Fargo, together with Elemental Excelerator, a leading nonprofit climate technology investor, and the New York City Energy Efficiency Corporation (NYCEEC), a leading nonprofit green bank, have joined forces to launch a new debt financing program, called Capital Access for Climate Innovators. The Capital Access Program was created to pilot innovative lending and co-investing vehicles to catalyze climate technology projects with significant community benefits.  

This collaboration aims to address funding gaps faced by climate technology companies, and particularly those led by traditionally excluded founders. Elemental and NYCEEC are partnering to identify and provide capital to Elemental portfolio companies who face finance gaps on their path toward commercialization and where debt capital can catalyze scale. To support this effort, Wells Fargo has provided a $400,000 grant, which will allow Elemental and NYCEEC to identify and share best practices and build financing tools and resources for climate technology companies, community lenders, credit enhancement providers and other project investors. 

“There’s an acute need for new kinds of financing and collaborations to support technology companies that are working to reduce GHG emissions,” said Curtis Probst, CEO of NYCEEC. “This partnership will help us create greener, cleaner and more affordable communities. We are excited to partner with Elemental to bring NYCEEC’s green lending to Elemental’s portfolio of climate tech innovators.” 

“At Elemental, we are profoundly aware of a $150 billion financing gap for climate technology projects scaling from early stage to widespread commercial adoption. With this partnership designed to reduce friction in accessing capital, we take an important step to bridge this gap and accelerate the deployment of climate projects with strong community benefits, like reduced utility bills, cleaner air, and more accessible transportation,” said Dawn Lippert, Founder and CEO of Elemental Excelerator.

Over the past decade, Elemental has supported over 150+ innovative climate technology companies through technical support and equity investments, while NYCEEC has provided debt financing to assist building owners, contractors, and developers in funding clean energy projects throughout NYC and the surrounding region. Through coordinated efforts, this partnership aims to supercharge the growth of climate technology companies and rapidly scale the number of projects they are able to deploy in communities throughout the country.

“We are proud to work together with Elemental Excelerator and NYCEEC to help strengthen the pipeline that can deploy capital for climate resilience,” said Robyn Luhning, Chief Sustainability Officer at Wells Fargo. “Across the communities we serve, we seek to accelerate solutions that support access to clean, affordable energy technologies and economic opportunity.” 

The announcement comes in the lead up to the Greenhouse Gas Reduction Fund and other important Inflation Reduction Act programs that will activate investors, from state and local green banks to community development finance institutions, to make climate solutions more affordable and accessible to low-income and other underserved communities across the country. Through this initiative, Elemental and NYCEEC will establish resources and frameworks that can be used across the climate tech investing ecosystem to support expanded funding opportunities that will be made available through the GGRF. 

About Elemental Excelerator
Elemental is a nonprofit investor in climate technologies with deep community impact. We bring more than a decade of experience across the climate sector, with an active and maturing portfolio of 150+ companies. Elemental fills two gaps fundamental to addressing climate change: funding projects for climate technologies in communities, and embedding equity and access into climate solutions. We invest in transformative technologies to create a systems change for a more resilient, equitable future. To learn more about Elemental’s team and our work in scaling climate technology with community impact, visit www.elementalexcelerator.com. 

About the New York City Energy Efficiency Corporation (NYCEEC)
NYCEEC is a nonprofit green bank sourcing funds from the public, private, and philanthropic sectors to support community clean energy projects through debt financing. Launched in 2010 by the New York City Mayor’s Office, NYCEEC has since expanded its geographical reach throughout the Northeast and Mid-Atlantic regions. NYCEEC’s mission is to deliver financing solutions and advance markets for energy efficiency and clean energy in communities. To date, NYCEEC has mobilized over $480 million to fund projects that are expected to eliminate over 1 million tons of CO₂e, with nearly 85% of those projects serving low-to-moderate income communities. To learn more about NYCEEC’s team and its Board of Directors, visit their website.

Contact: [email protected]

SOURCE Elemental Excelerator

• Ryvu has met the conditions for receiving EUR 8 million in Tranche A of venture debt from the European Investment Bank (EIB) due to the progress within the RVU120 program among other factors.
• Pursuant to the agreement concluded with EIB, Ryvu still has access to a further EUR 14 million over two additional tranches. The disbursement of funds is subject to specific conditions outlined in the agreement.
• Together with various sources, this financing secures Ryvu’s cash runway until Q1 2026.

KRAKOW, Poland, March 6, 2024 — Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that on March 5, 2024 it has received formal confirmation of the fulfillment of the conditions necessary for the disbursement of the Tranche A of EUR 8 million venture debt from the European Investment Bank (EIB), under the financing agreement concluded on August 16, 2022.[KS1] [JJ2]  The offer of disbursement of Tranche A was issued by EIB, among other factors specified in the financing agreement, due to the successful transition of the RVU120 program from Phase I to Phase II of clinical development. The company is expecting to receive PLN 8 million payment on March 13, 2024.

In August 2022, Ryvu announced that the EIB would provide up to a total of EUR 22 million, and this EUR 8 million represents the first tranche. The funds are being provided under the EIB’s venture debt instrument, which is tailored to the specific financing needs of high-growth innovative companies. The European Fund for Strategic Investments, part of the Investment Plan for Europe, is backing this funding with a guarantee. 

“We are excited that the progress of RVU120 now allows us to access the funds to help accelerate the development of our lead program and the rest of Ryvu’s pipeline. Together with different sources, the financing secures Ryvu’s cash runway until Q1 2026.“, said Pawel Przewiezlikowski, Chief Executive Officer of Ryvu Therapeutics. “We expect that further progress on Phase II RVU120 clinical development will enable Ryvu to fulfill the requirements and obtain the remaining EUR 14 million from the EIB.” 

The EIB’s financial support will help Ryvu finance its development pipeline of new cancer treatments, from discovery to clinical trials. Ultimately, Ryvu aims to address the clinical limitations of current treatments in oncology and provide patients with access to innovative therapies for hematologic and solid tumors. 

About Ryvu Therapeutics    

Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small-molecule therapies that address emerging targets in oncology. Internally discovered pipeline candidates use diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, and immuno-oncology targets. 

Ryvu’s most advanced programs include RVU120, a selective CDK8/CDK19 kinase inhibitor with the potential to treat hematological malignancies and solid tumors, currently in Phase II development (i) as a monotherapy for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) and high-risk myelodysplastic syndromes (HR-MDS) as well as (ii) in combination with venetoclax for the treatment of patients with r/r AML. Another clinical program, SEL24 (MEN1703), is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group. Ryvu Therapeutics has signed multiple partnering and licensing deals with global companies, including BioNTech and Exelixis. 

The Company was founded in 2007 and is headquartered in Kraków, Poland. Ryvu is listed on the Warsaw Stock Exchange and is a component of the mWIG40 index. For more information, please see www.ryvu.com. 

SOURCE Ryvu Therapeutics

Up-round investment to accelerate vertical and regional expansion, product innovation, and strategic partnerships

NEW YORK, March 6, 2024 — Claroty, the cyber-physical systems protection company, today announced it has secured $100 million in strategic growth financing. Participants include lead equity investor Delta-v Capital, as well as AB Private Credit Investors at AllianceBernstein, Standard Investments, Toshiba Digital Solutions, SE Ventures, Rockwell Automation, and Silicon Valley Bank, a division of First Citizens Bank. Combined with Claroty’s existing $635 million in funding to date, this new financing further establishes the company’s leadership position in the critical infrastructure cybersecurity market.

The funds will be used to scale Claroty’s platform approach to cyber-physical systems (CPS) protection across key verticals including the public sector and heavily regulated critical infrastructure industries, expand in emerging regions across the Americas, EMEA, and Asia-Pacific, fuel research and development for core and adjacent technologies including secure remote access, and double down on new and existing strategic partnerships.

“The past year has brought unprecedented geopolitical, macroeconomic, and regulatory changes that have created new trends and challenges for those charged with protecting the world’s critical infrastructure,” said Yaniv Vardi, CEO of Claroty. “With our deep domain expertise, unmatched technological capabilities in our comprehensive platform, and extensive partner ecosystem, Claroty is uniquely equipped to help CPS defenders navigate these changes. This new investment reinforces our leadership position in the CPS security market and propels us forward on our journey to ensure the cyber and physical worlds can safely connect to drive progress, improve productivity, and support our lives.”

The financing comes shortly after a momentous year for Claroty, which now works with 20% of the Fortune 100. Recent growth milestones, industry recognition and industry accolades include:

• Revenue: Surpassed $100 million in annual recurring revenue (ARR) during 2023
• Customers: Achieved over 300% growth in number of customers since 2020
• Partners: Established strategic technology alliances with industry leaders such as CrowdStrike, ServiceNow, and AWS; added several Managed Security Service Providers (MSSPs) including IBM, Rockwell Automation, Schneider Electric, NTT Data, and eSentire to its FOCUS Partner Program
• Product Innovation: Enhanced its SaaS offerings with new vulnerability and risk management (VRM) capabilities, further empowering security teams to evaluate and strengthen their organization’s CPS risk posture
• Threat Research: Team82, Claroty’s award-winning research team, has discovered and disclosed over 550 CPS vulnerabilities to date
• Analyst Recognition: Named a Leader or relevant vendor in numerous industry analyst reports, including:
  • KLAS Research, Best in KLAS for Healthcare IoT Security, four years in a row
  • Everest Group, Operational Technology (OT) Security Products PEAK Matrix® Assessment 2023 – Leader
  • Westlands Advisory, 2023 IT/OT Network Protection Platforms Navigator™ – Leader
  • Quadrant Knowledge Solutions, SPARK Matrix™: Operational Technology (OT) Security Q4 2023 – Leader
  • Quadrant Knowledge Solutions, SPARK Matrix™: Connected Medical Device Security Solution, Q4 2023 – Leader
  • Gartner®, 2023 Market Guide for CPS Protection Platforms – A Representative Vendor¹
  • Forrester, The Operational Technology Security Solutions Landscape, Q1 2024 – Notable Vendor
• Awards: Named to the Deloitte Technology Fast 500 for three years in a row, the Forbes Cloud 100 for two years in a row, and the inaugural Fortune Cyber 60
• Leadership: Added considerable talent to its leadership team with the appointments of Derek Phillips as Chief Revenue Officer, Shira Bar Yosef (Weizman) as its first-ever Chief Customer Officer, and former U.S. National Cyber Director Chris Inglis and Amtrak CISO Jesse Whaley as advisory board members

“The lines between the digital and physical worlds are blurring, which means that cyber attacks and incidents are having more physical, real-world impacts such as power outages, fuel shortages, and disruptions to medical care,” said Dan Williams, Partner at Delta-v Capital. “Claroty has demonstrated a unique ability to address critical infrastructure organizations’ most pressing security needs, and we believe its platform approach to CPS protection is strongly aligned with where the market is headed for years to come. We are excited to join such an important mission and look forward to supporting Claroty’s continued growth and success.”

“As our world becomes more digitally connected, cybersecurity becomes an increasingly urgent priority, especially when critical infrastructure is involved,” said Lewis Leavitt, Director at AB Private Credit Investors. “Claroty has proven that its talented leadership team, advanced technology, and go-to-market strategy comprise the key ingredients for long-term growth, and we are delighted to come aboard at such an exciting time in the company’s journey,” continued Alex Barry, Managing Director at AB Private Credit Investors.

“The New York Corporate Banking team is excited to support Claroty with this new strategic growth financing,” said Sameer Paul, Director of Silicon Valley Bank. “We have witnessed the company’s impressive success and strong growth while providing critical needs for the cybersecurity market. The Claroty team shows true professionalism and are the type of strong operators SVB loves to support. We look forward to partnering with the company as they continue to grow and scale.”

¹ Gartner, Market Guide for CPS Protection Platforms, 29 June 2023, Katell Thielemann, Wam Voster.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
GARTNER and Magic Quadrant are registered trademarks and service marks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

About Claroty

Claroty empowers organizations to secure cyber-physical systems across industrial, healthcare, commercial, and public sector environments: the Extended Internet of Things (XIoT). The company’s unified platform integrates with customers’ existing infrastructure to provide a full range of controls for visibility, risk and vulnerability management, threat detection, and secure remote access. Backed by the world’s largest investment firms and industrial automation vendors, Claroty is deployed by hundreds of organizations at thousands of sites globally. The company is headquartered in New York City and has a presence in Europe, Asia-Pacific, and Latin America. To learn more, visit claroty.com.

SOURCE Claroty

Tava Health’s all-in-one platform prioritizes therapists and increases accessibility for individuals seeking quality mental health care.

SALT LAKE CITY, March 6, 2024 — Tava Health, a trailblazing mental health company, successfully completed a $20 million Series B funding round led by Catalyst Investors. Existing investors Peterson Partners, Toba Capital, and SpringTide, along with new investor Blue Heron Capital, also participated in the funding round. The new capital will be utilized for extensive product development, expansion of Tava Health’s provider network, and bolstering partnerships with employers and health insurance carriers. Kapil Desai, partner with Catalyst Investors, will join the company’s Board of Directors as part of the investment.

“Demand for therapy is greater than ever, and while access to mental health care is improving, we still face a crisis of access and quality,” said Desai. “We are confident in Tava’s innovative approach to mental health and proud to back a company that successfully delivers a complete solution for therapists, enabling them to do what they do best – helping clients when they need it, how they need it, and where they need it.”

Tava Health’s therapist-centric model sets it apart in the mental health market. The company prioritizes therapists, providing open access to Tava’s electronic medical record (EMR) and practice management software, empowering therapists to deliver top-notch care to patients in a full-stack platform.

“We developed Tava with therapists at the center, recognizing that their needs are rarely prioritized. By equipping therapists with tools to make them more productive, they can increase time with patients providing mental health care that is so desperately needed,” said Dallen Allred, CEO of Tava Health. “In a mental health landscape where timely access to care is crucial, Tava Health is a beacon of efficiency and accessibility.”

Tava Health has inked agreements with national carriers such as Aetna and UHC in the last year, broadening access to continuous care for patients. The company has also expanded its local partnerships, establishing ties with 45 regional medical carriers.

Tava Health’s commitment to prioritizing therapists translates into industry-leading accessibility and minimal wait times, ensuring that individuals seeking mental health support can swiftly connect with qualified professionals. With Tava, patients can access care quickly, as early as the same day. Tava Health is able to do this without sacrificing quality, as its therapists receive a 4.94 out of 5 stars on average, underscoring the positive impact of a therapist-centric approach on client satisfaction and overall mental health treatment experience.

About Tava Health

Founded in 2019, Tava Health is a cutting-edge mental health platform revolutionizing access to quality care. Bridging the gap between providers and those seeking support, Tava Health prioritizes therapists, offering an integrated suite with an electronic medical record, telehealth, billing, and referral management. Committed to breaking down barriers, Tava Health partners with employers, making mental health checkups as routine as other healthcare practices. For more information, visit www.tavahealth.com.

About Catalyst Investors

Catalyst Investors is a growth equity firm based in New York. Over the past 20-plus years, Catalyst has invested in rapidly growing technology companies and has established a successful track record of partnering with entrepreneurs and helping companies scale. Recent investments and exits include Breezeway, BrightFarms, ChowNow, Clinicient, EDB, Fusion, LinkSquares, Pax8, Presence and Weave. For more information, visit www.catalyst.com.

SOURCE Tava Health, Inc.

Newly secured capital to drive growth across Fantasy, Sportsbook, Casino, and Media divisions – Betr also announced strategic hires with the addition of a Head of Media Revenue, Partnerships, and Strategy and Head of Government Affairs           

MIAMI, March 6, 2024 — Betr Holdings, Inc. (“Betr”) today announced it has closed $15 million in strategic equity financing from a premier group of investors at a $375 million valuation, bringing its total funding to date to $100 million. The round was co-led by Harmony Partners and 10x Capital, with participation from the company’s three largest existing investors: Fuel Venture Capital, Aliya Capital Partners, and Roger Ehrenberg/Eberg Capital, alongside others. This round of financing comes off a highly successful 2023 for Betr, where the company reached a significant level of scale – both with respect to paying users and revenue – while doing so efficiently and profitably.     

Betr recently announced market access expansion plans for its Online Sportsbook product, having secured market access in Pennsylvania, Ohio, Virginia, Indiana, Colorado, and Kentucky, as well as the upcoming launch of its Casino product (pending regulatory approval), with the company also securing iGaming market access in Pennsylvania. Betr has also officially received its temporary Indiana sports wagering license from the Indiana Gaming Commission in recent weeks.

Betr also recently announced that it has fortified its senior leadership team, hiring Dan Maas as Head of Media Revenue, Partnerships, and Strategy and hiring Andrew Winchell as Head of Government Affairs. Dan joins Betr from Wave Sports & Entertainment, where he worked his way up from VP of Partnerships to EVP of Commercial and oversaw the development and monetization of highly successful premium franchises, including New Heights with Travis and Jason Kelce and Podcast P with Paul George, in addition to leading the monetization of their successful original short form video focused social media content strategy, which are both highly synergistic to the core pillars of Betr Media. Dan will lead monetization efforts for Betr Media, positioning Betr’s media arm to become a large bona fide revenue-generating business – in addition to the primary benefit Betr Media serves, which is to create unfair customer acquisition economics for Betr Gaming. Andrew joins Betr from FanDuel, where he served as their Directory of Regulatory Affairs. Andrew brings a breadth of experience working closely with state regulators and political leaders on key issues pertaining to sports gaming and will meaningfully strengthen Betr’s internal government and regulatory affairs capabilities as the company scales in size and launches in new jurisdictions.

“We are thrilled to announce our strategic equity financing, new members of our senior leadership team, and the approval of our temporary Indiana sports wagering license,” said Joey Levy, Founder and CEO of Betr. “Jake (Paul) and I co-founded Betr just over two years ago, so raising capital from leading growth stage investors at a $375 million valuation in the very early days of our business is a testament to the performance of the team and business to date, and the potential we have to build a category defining business with Betr. Finally, I want to thank the Indiana Gaming Commission for the honor and privilege of a sports wagering license in the Hoosier state. We are excited to launch our new V1 Sportsbook product in Indiana over the coming months, while bringing our best-in-class responsible gaming standards to the state.”

Harmony Partners is a leading growth investor funding breakout emerging companies led by Mark Lotke, who led the software group at FTV Capital, led the pre-IPO group at Internet Capital Group, and prior to that was at General Atlantic. 10X Capital is a prolific venture capital firm led by co-founders Hans Thomas and David Weisburd having invested in companies including 23andMe, Palantir, Robinhood, and Udemy. 10X Capital was a significant investor in DraftKings going back to July 2018.

“We believe that Betr has the product, management and market opportunity that we saw in DraftKings in its early days with a significantly larger TAM and room for growth today,” said David Weisburd, Co-Founder and Head of Venture Capital at 10x Capital.

About Betr 

Founded in 2022 by Joey Levy and Jake Paul, Betr is a leading sports gaming and sports media company focused on enhancing the consumption of sports through entertainment. Betr’s gaming products are differentiated through a unique product experience with a simplified user interface that is catered to the casual sports fan, enabling Betr to capture more of the underpenetrated online gaming addressable market. Betr began with a beta version of its Online Sports Betting (OSB) product, which only offered microbetting markets such as the next play in a football game or the next pitch in a baseball game, before launching its real-money Daily Fantasy Sports (DFS) product, Betr Picks, in 24 states. Betr plans on launching its V1 Sportsbook product with full sportsbook capabilities ahead of the 2024 NFL season, as well as its iGaming vertical with the launch of Betr Casino by the end of 2024. Betr’s media division, Betr Media, is the fastest growing sports betting media brand in the United States that has grown to over 2.5 million followers, 2.6 billion impressions, and 140 million engagements across its social channels since publicly launching in August 2022. Betr Media is able to effectively reach and engage its audience at scale given its large social following coupled with its unique combination of in-house media talent and production, with an emphasis on original short-form video content. 

For more information on Betr, visit betr.app or follow @betr on TikTok, Instagram, and Twitter. To learn more about responsible play, please visit betr.app/responsibility. 

SOURCE Betr Holdings, Inc.

New financing round, led by Next Coast Ventures, S3 Ventures, and UPMC Enterprises, positions Company for continued growth, innovation, and integration 

BrainCheck expands Board of Directors with appointment of Nicholas Shapiro as New Board Member, further strengthening the Company’s strategic leadership

AUSTIN, Texas, March 6, 2024 — BrainCheck, Inc., a digital health innovator delivering first-of-its-kind technology into the growing digital cognitive assessment market, today announced a $15 million new financing round, led by Next Coast Ventures, S3 Ventures, and UPMC Enterprises, the innovation, commercialization, and venture capital arm of UPMC. The Company also expanded its Board of Directors with the appointment of Nicholas Shapiro, Vice President, UPMC Enterprises, as a new board member, further strengthening the Company’s strategic leadership.

The funding will accelerate BrainCheck’s commercial traction, expand innovation within its product portfolio, build upon existing clinical evidence, and extend the Company’s impact throughout the healthcare landscape, including major integrations with healthcare systems. This announcement follows the recent launch of BrainCheck’s next generation platform and 3-minute screening solution, which empowers clinicians to screen and monitor patients’ cognitive function anytime, anywhere.

“We are laser focused on commercializing and scaling a digital cognitive assessment platform that is clinically robust, easy for patients and their caregivers to use, enables a simplified provider experience and improves access to the actionable information needed to intervene sooner and potentially combat cognitive decline,” said Kim Rodriguez, CEO of BrainCheck. “We thank our current and new investors for their continued support and look forward to deploying this capital to play an important role in revolutionizing cognitive care.”

“We believe in BrainCheck’s vision to pioneer a fundamental shift in how cognitive care is delivered,” said Michael Smerklo, Co-Founder and Managing Partner of Next Coast Ventures. “Dementia is projected to impact 14 million people in the United States and 152 million globally in the coming decades, underscoring the importance of proactive measures to address prevention, early detection, and effective management strategies.^i,ii“

Trusted by hundreds of the country’s most prestigious providers and specialists, BrainCheck’s clinically proven platform is the most comprehensive solution commercially available across the cognitive care continuum, streamlining screening, assessment, care planning and monitoring.

“Our decision to invest in BrainCheck is fueled by a deep understanding of the pressing burden of cognitive impairment on health care and the exciting solutions on the horizon to advance the industry. I am honored to join BrainCheck’s Board of Directors and look forward to working collaboratively with the team to drive strategic initiatives and shape the future growth trajectory of the Company,” said Nicholas Shapiro, Vice President, UPMC Enterprises. “BrainCheck’s solutions offer rapid, reliable resources to support accurate assessments, stratify individual risk, and deliver actionable insights that can help all stakeholders – patients, caregivers, providers, and risk-bearers.”

For more information about BrainCheck and its innovative cognitive assessment solutions, please visit www.braincheck.com.

About BrainCheck
To learn more, please visit braincheck.com.

Contact:
[email protected]

________________________________
ⁱ 2022 Alzheimer’s disease facts and figures. Alzheimers Dement. 2022 Apr;18(4):700-789. doi: 10.1002/alz.12638. Epub 2022 Mar 14. PMID: 35289055.

ⁱⁱ GBD 2019 Dementia Forecasting Collaborators: “Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019.” The Lancet Public Health, January 6, 2022.

SOURCE BrainCheck, Inc.

– Company positioned to have four compounds in clinical trials in 2024 including three NBD1 stabilizers and one ICL4 modulator –

– Edd Fleming, M.D., of Enavate Sciences joins company’s Board of Directors –

BOSTON, March 6, 2024 — Sionna Therapeutics, a clinical-stage life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF), today announced the closing of a $182 million Series C financing to support the clinical development of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein by stabilizing the first nucleotide-binding domain (NBD1).  

The Series C round, which was upsized and oversubscribed, was led by Enavate Sciences with additional new investors Viking Global Investors and Perceptive Advisors, as well as participation by all existing investors including RA Capital, OrbiMed, TPG’s The Rise Fund, Atlas Venture, the Cystic Fibrosis Foundation, funds and accounts advised by T. Rowe Price Associates, Inc., and Q Healthcare Holdings, LLC., a wholly owned subsidiary of QIA. Sionna also announced today that Edd Fleming, M.D., Executive Vice President of Commercialization at Enavate Sciences, is joining its Board of Directors.

“We have deep experience in CF and a sharp focus on advancing the development of novel small molecules targeting NBD1 and complementary modulators that enable the potential for full restoration of CFTR function for most people living with CF,” said Mike Cloonan, President and Chief Executive Officer of Sionna. “We are encouraged by the strong interest and validation from the excellent investors in our upsized Series C financing. This capital raise provides financial flexibility positioning us to execute our clinical development plan with funding through 2026 and multiple value-creating clinical readouts. We are also pleased to welcome Dr. Fleming to our Board and look forward to insights from his more than 30 years of experience in the health care industry.”

CF is caused by mutations in the CFTR gene, which codes for an epithelial ion channel that is essential for producing healthy, freely flowing mucus in the airways, digestive system, and other organs. The most common mutation in CFTR, ΔF508, causes NBD1 to unfold at body temperature and severely impairs CFTR function.

Sionna has presented preclinical data, including data from the clinically predictive human bronchial epithelial cell (CFHBE) model, that demonstrate its NBD1 stabilizers can restore ΔF508-CFTR maturation, trafficking, and function to wild-type levels when combined with complementary modulators. A Phase 1 clinical trial of its first clinical-stage NBD1 stabilizer, SION-638, has identified doses that are generally safe and well tolerated, and target exposure (based on the CFHBE assay) was achieved at all doses, with more time above target with increasing dose.

Sionna has nominated two additional NBD1 stabilizers from its second series, SION-451 and SION-719, and plans to advance both compounds to clinical trials in 2024 pending results from ongoing Good Laboratory Practice (GLP) toxicology studies. In addition, the company is continuing to advance the development of compounds targeting complementary mechanisms including SION-109, which targets NBD1’s interface with the CFTR intracellular loop 4 (ICL4) region; a Phase 1 clinical trial with SION-109 began in January 2024.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Building on over a decade of extensive research on the genetic mutations associated with CF and founded in 2019, Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ΔF508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of NBD1, the key and unique mechanism to enable full restoration of ΔF508-CFTR function, and complementary programs targeting ICL4 and TMD1. Sionna’s pipeline has the potential to deliver best-in-class efficacy and reach previously unachievable levels of long-term benefit for people with CF. For information about Sionna visit https://www.sionnatx.com/.

Media Contact
Adam Daley
Berry & Company Public Relations
212.253.8881
[email protected] 

Investor Contact
[email protected] 

SOURCE Sionna Therapeutics

Yuno, a leading global payments orchestration platform, announces today it has secured $25 million from a consortium of prominent investors, including DST Global Partners, Andreessen Horowitz, Tiger Global, Kaszek Ventures and Monashees.

NEW YORK, March 5, 2024 — Yuno, a leading global payments orchestration platform, announces today it has secured $25 million from a consortium of prominent investors, including DST Global Partners, Andreessen Horowitz, Tiger Global, Kaszek Ventures and Monashees.

Founded by experienced tech entrepreneurs Juan Pablo Ortega and Julián Núñez, Yuno offers its clients fast and reliable payments orchestration, helping revolutionize retail, e-commerce, travel, mobility, and other industries. Yuno already serves customers like McDonald’s, Avianca, inDrive, Rappi, and others across 40 countries, offering innovative features such as one-click checkout modifications, smart routing, and the integration of information from all payment processors and anti-fraud tools into a unified interface.

Funds raised in this Series A round will help further strengthen Yuno’s operations in North and South America and enter new markets in Europe, Asia, and Africa. This should benefit Yuno’s customers, who already value the company’s innovative approach to integrating diverse payment methods, which is fueling their own growth by providing easy-to-use, reliable, and tailored solutions for different geographies.

Juan Pablo Ortega, CEO and Co-founder at Yuno, commented: “This financial backing validates our vision and our ability to take the global payments industry into the future, helping fuel positive change across many different sectors of the economy. We are thrilled to bring our cutting-edge solutions to new markets.”

Julián Núñez, Co-founder at Yuno, added: ”Yuno is already successfully facilitating financial transactions in over 40 countries, highlighting our versatility and adaptability in meeting the diverse demands of the global market. This latest round of funding will play a pivotal role in advancing Yuno’s technological infrastructure, expanding our team of exceptional professionals, and crafting innovative market strategies to strengthen our presence across different geographies.”

“We’re happy to be supporting Yuno in the next phase of its growth,” said Saurabh Gupta, managing partner at DST Global. “We’re impressed by the entrepreneurial track record of its founders, the strong team and customer base they’ve built, and the company’s proven ability to keep innovating in online payments.”

Contact:
Yuno
***@y.uno

Photos:
https://www.prlog.org/13010184

Press release distributed by PRLog

SOURCE Yuno